Who is sponsoring NCT05959252?

NCT05959252 is sponsored by Sydney Local Health District.

What drugs are being tested in NCT05959252?

Interventions in NCT05959252: Unfractionated heparin, Bivalirudin.

What condition does NCT05959252 study?

NCT05959252 studies Extracorporeal Membrane Oxygenation Complication.

Is NCT05959252 still recruiting?

NCT05959252 is currently recruiting now. Last updated 13 August 2024.

Last reviewed 2024-08-13 · How we verify

NCT05959252: BLUSH

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

BivaLirudin versUS Heparin in Extracorporeal Membrane Oxygenation

Recruiting now Phase 2 Last updated 13 August 2024

What this trial tests

Phase 2 trial testing Unfractionated heparin in Extracorporeal Membrane Oxygenation Complication in 80 participants. Currently enrolling.

Timeline

1 May 2024

Primary endpoint
1 December 2025

1 May 2026

Quick facts

Lead sponsor	Sydney Local Health District
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	80
Start date	1 May 2024
Primary completion	1 December 2025
Estimated completion	1 May 2026
Sites	1 location across Australia

Drugs / interventions tested

Unfractionated heparin — full drug profile →
Bivalirudin (BIVALIRUDIN) — full drug profile →

Conditions studied

Extracorporeal Membrane Oxygenation Complication — all drugs for Extracorporeal Membrane Oxygenation Complication →

Sponsor

Sydney Local Health District — full company profile →

Who can join

18 and older, any sex, with Extracorporeal Membrane Oxygenation Complication. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this open label randomised clinical trial is to compare Bivalirudin versus Heparin for anticoagulation in patients requiring extracorporeal membrane oxygenation support. The main question it aims to answer are include the ability to maintain anticoagulation within defined therapeutic range, bleeding and thrombotic complications and a comparison of the total cost of anticoagulation care. Participants will be randomised to either anticoagulation with Bivalirudin or anticoagulation with Unfractionated Heparin.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Anticoagulation in venovenous extracorporeal membrane oxygenation.
Jung C, Stueber T, Mirus M, Heubner L, et al · · 2025 · cited 5× · PMID 40103791 · DOI 10.3389/fmed.2025.1530411
Between a rock and a hard place: anticoagulation management for ECMO.
Buchtele N, Levy JH. · · 2024 · cited 5× · PMID 38457000 · DOI 10.1007/s00063-024-01116-0
Extracorporeal membrane oxygenation for cardiac arrest: what, when, why, and how.
Brandorff M, Owyang CG, Tonna JE. · · 2023 · cited 1× · PMID 38009280 · DOI 10.1080/17476348.2023.2288160
Anticoagulation during extracorporeal membrane oxygenation: questioning the current standards in balancing the risks of thrombosis and bleeding.
Gratz J, Buscher H, Schaden E. · · 2025 · PMID 40877110 · DOI 10.1016/j.bja.2025.07.060

Verify or expand the search:

Other trials of Unfractionated heparin

Trials testing the same drug.

NCT07361783 — Impact of Pre-Hospital Heparin Loading in STEMI Patients for Primary PCI: The HELP-PCI 2 Trial · NA · recruiting
NCT06442267 — Comparing Anticoagulation Strategies Using UFH, Argatroban and LMWH for ECMO Support · Phase 4 · recruiting
NCT06174961 — The Effect of Exercise on Pharmacodynamics and Pharmacokinetics of a Single Dose of Unfractionated Heparin · Phase 4 · completed
NCT05255848 — Nebulised Heparin in Patients With COVID-19 Pneumonia · Phase 2, PHASE3 · unknown
NCT05247424 — Pretreatment With Unfractionated Heparin for ST Elevation Myocardial Infarction · Phase 4 · completed

Other recruiting trials for Extracorporeal Membrane Oxygenation Complication

Currently open trials in the same condition.

NCT06814340 — "Continuous Positive Airway Pressure on Venovenous extracorporeaL Membrane Oxygenation for Acute respIratory Distress sy · Phase 3 · recruiting
NCT06469801 — ECMO ABI Detection With Hyperfine · NA · recruiting
NCT06276010 — Use of Nafamostat Mesilate for Anticoagulation in Patients With ECMO · NA · recruiting
NCT06275555 — Use of Bivalirudin for Anticoagulation in Patients With Extracorporeal Membrane Oxygenation · NA · recruiting
NCT06792643 — Cangrelor on Top of anticoagUlation in Patients With myocaRdial Infarction-related Cardiogenic Shock/Cardiac Arrest rece · Phase 2 · recruiting

Other Sydney Local Health District trials

Trials by the same sponsor.

NCT06552312 — A Modified Delphi for ECPR Post Resuscitation Care · active not recruiting
NCT06578468 — End-Tidal Oxygen for Intubation in the Emergency Department · NA · recruiting
NCT05006339 — The Use of Remote Monitoring for Orthodontic Retention Review · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05959252 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sydney Local Health District
Last refreshed: 13 August 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05959252.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing